SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-20-006934
Filing Date
2020-05-07
Accepted
2020-05-07 16:03:14
Documents
67
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aeri-20200331.htm   iXBRL 10-Q 1479392
2 EX-31.1 aeri3312020ex311.htm EX-31.1 16330
3 EX-31.2 aeri3312020ex312.htm EX-31.2 16325
4 EX-32.1 aeri3312020ex321.htm EX-32.1 10512
5 EX-32.2 aeri3312020ex322.htm EX-32.2 10454
  Complete submission text file 0001628280-20-006934.txt   6715115

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aeri-20200331.xsd EX-101.SCH 39084
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT aeri-20200331_cal.xml EX-101.CAL 60205
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT aeri-20200331_def.xml EX-101.DEF 216353
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aeri-20200331_lab.xml EX-101.LAB 526463
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aeri-20200331_pre.xml EX-101.PRE 351696
21 EXTRACTED XBRL INSTANCE DOCUMENT aeri-20200331_htm.xml XML 1272475
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36152 | Film No.: 20856220
SIC: 2836 Biological Products, (No Diagnostic Substances)